BladderBoneBrainBreastCervicalColonEsophagealKidneyLaryngealLeukemia CancerLiverLungLymphomaMouthOvarianPancreaticProstateRectalSkinTesticularThroatUterineHeart / Stroke-RelatedHigh Cholesterol Heart / Stroke-RelatedResearch & DevelopmentCardiologyDiabetes & EndocrinologyFamily PracticeInternal MedicinePharmacyBladder CancerBone CancerBrain CancerBreast CancerCervical CancerColon CancerEsophageal CancerKidney CancerLaryngeal CancerLeukemiaLiver CancerLung CancerLymphoma CancerMouth CancerOvarian CancerPancreatic CancerProstate CancerRectal CancerSkin CancerTesticular CancerThroat CancerCancerUterine CancerCardiovascular DiseasesHigh CholesterolHealth TechnologyResearch And Development
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
TUESDAY, March 27 (HealthDay News) -- For statin-treated patients with high levels of low-density lipoprotein (LDL) cholesterol, concomitant treatment with a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9) is associated with a further reduction in LDL cholesterol, according to a study published in online March 26 in the Journal of the American College of Cardiology to coincide with presentation at the annual meeting of the American College of Cardiology, held from March 24 to 27 in Chicago.
Noting that statin therapy stimulates production of PCSK9, James McKenney, Pharm.D., from Virginia Commonwealth University in Richmond, and colleagues investigated the effect of blocking PCSK9 using the monoclonal antibody SAR236553/REGN727. A total of 183 patients with an LDL cholesterol reading of 100 mg/dL or higher who had already been treated with atorvastatin for more than six weeks were randomly allocated to six groups: placebo; SAR236553/REGN727 every two weeks (Q2W) at a dose of 50, 100, or 150 mg; or SAR236553/REGN727 every four weeks (Q4W) at 200 or 300 mg, alternating with placebo for 12 weeks.
The researchers found that there was a dose-response to SAR236553/REGN727 injections. Patients assigned to 50, 100, and 150 mg Q2W had a 40, 64, and 72 percent reduction, respectively, in circulating LDL cholesterol. Patients who received 200 or 300 mg injections Q4W had reductions of 43 and 48 percent, respectively. There was a 5 percent reduction seen in the placebo group.
"These encouraging results suggest the need for further evaluation of SAR236553 in larger, even more diverse patient populations, and with different background therapies, to fully assess its efficacy and safety," the authors write.
Several authors disclosed financial ties to pharmaceutical companies, including Sanofi and Regeneron Pharmaceuticals, both of which funded the study and together manufacture SAR236553/REGN727.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.
Updated on June 05, 2022
Read this Next
Other Trending Articles